Verve And Lilly Relationship Expands To Include Verves In Vivo Gene Editing Programs Targeting PCSK9 And ANGPTL3
Lilly acquires product rights to Verve's lead cardiovascular programs from Beam Therapeutics
BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical biotechnology company pioneering a new approach to treating cardiovascular disease with single-drug gene-editing drugs, today announced the collaboration to expansion. with Eli Lilly and Company (Lilly). Lilly has acquired certain product rights from Beam Therapeutics for Verve's in vivo cardiovascular gene modification programs targeting PCSK9 and ANGPTL3 , as well as a third undisclosed cardiovascular disease (CVD) target. Verve's PCSK9 product candidates, VERVE-101 and VERVE-102, and ANGPTL3 product candidate, VERVE-201, are designed to provide potent, long-term, lifelong reductions in low-density lipoprotein cholesterol levels in patients with chronic diseases. . or development risk. , the most common form of cardiovascular disease.
For the PCSK9 and ANGPTL3 product candidates, Lilly now owns the rights to the products previously owned by Beam, including the right to a 33% share of global development costs, as well as commercialization and shared distribution of profits and related costs . USA. on a 50/50 basis. Verve owns all rights to the PCSK9 and ANGPTL3 products outside the United States. Under the collaboration agreement, Verve retains control over the development and marketing of all collaboration products. Additionally, Lilly has also received co-financing and potential profit-sharing rights from Beam on similar terms for a third undisclosed target in cardiovascular disease.
"We are very excited to have Lilly as a potential long-term partner in the next phase of development of our gene editing techniques for people with ASCVD," said Sekar Kattiresan, MD, co-founder and CEO of Verve. “Lilly brings valuable cardiometabolic knowledge as well as experience in commercializing products for broad applications. Lilly's significant investment to acquire the rights to Beam's products underscores Lilly's confidence in Verve's preclinical and interim clinical data and programs. We continue to be impressed by Lilly's commitment to genetic medicine, and his team's interest in applying gene editing technology to the cardiometabolic space aligns closely with Verwe's vision.
Ruth Gimeno, PhD, vice chair of Lilly's Diabetes, Obesity and Cardiometabolism Research Group, added: “Gene editing is an exciting new frontier for medicine that can provide long-term efficacy with a single treatment. Verve is a leader in the development of gene-edited treatments for cardiovascular disease, and we are excited to expand our relationship with Verve to develop much-needed new treatment options for people with cardiovascular disease.
The deal represents an expansion of the relationship between Verve and Lilly. In early June 2023, Verve and Lilly entered into an exclusive research collaboration to advance Verve's preclinical program for in vivo gene modification targeting lipoprotein (a).
About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage gene medicine company that is pioneering a new approach to treating cardiovascular disease, potentially transforming chronic therapy treatments into single-use gene-editing drugs. The company's first three programs, VERVE-101, VERVE-102 and VERVE-201, target genes that have long been tested as targets for lowering low-density lipoprotein (LDL) cholesterol, a major cause of cardiovascular disease. deadline. a long-term reduction in the level of LDL in the blood. VERVE-101 and VERVE-102 are designed to permanently inactivate the PCSK9 gene in the liver and are being developed initially for the treatment of heterozygous familial hypercholesterolemia (HeFH) and eventually for the treatment of patients with atherosclerotic cardiovascular disease (ASCVD). ), who cannot reach treatment. the goals. Oral therapy. VERVE-201 is designed to permanently inactivate the ANGPTL3 gene in the liver and is being developed initially for the treatment of homozygous familial hypercholesterolemia (HoFH) and eventually for the treatment of patients with refractory hypercholesterolemia. For more information, visit www.VerveTx.com.
Caution Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve significant risks and uncertainties, including statements about possible benefits and results that may be obtained from our collaboration with Lilly; whether Lilly will exercise its right to participate in any of the collaborative programs; and the therapeutic potential of the Company's programs. All statements, other than statements of historical fact, contained in this press release, including statements regarding the company's strategy, future operations, future financial condition, prospects, plans and management objectives, are forward-looking statements. The words "anticipate", "estimate", "proceed", "may", "estimate", "expect", "aim", "may", "plan", "potential", "anticipate", "project". "should," "target," "will," "will" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All forward-looking statements are based on management's current expectations regarding future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the Company's limited operating history; the Company's ability to submit and obtain timely regulatory approvals for its product candidates; promote its product candidates in clinical trials; initiate, enroll and complete current and future clinical trials as planned or at all; appropriately assess the potential patient population and/or market for the Company's potential products; reproduce in clinical studies the positive results obtained in preclinical studies and/or initial clinical trials of VERVE-101, VERVE-102 and VERVE-201; advance the development of its product candidates as anticipated in current and future clinical trials; obtain, retain or protect intellectual property rights in its product candidates; manage costs; and raise significant additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties and other important factors, any of which could cause the company's actual results to differ from those contained in forward-looking statements, see “Risk Factors,” as well as a discussion of possible risks. uncertainties and other important factors in the Company's most recent filings with the Securities and Exchange Commission and in other documents that the Company will file in the future with the SEC. In addition, the forward-looking statements contained in this press release reflect the views of the Company as of the date hereof and should not be relied upon as the views of the Company at any date after the date hereof. The Company hopes that subsequent events and developments will cause the Company to change its views. However, although the Company may decide to update these forward-looking statements at some point in the future, the Company disclaims any obligation to do so.
Contacts of Verve Investor:
This is Robinson
jrobinson@vervetx.com
Verve Media contacts
Ashley Kasikowski
1AB
ashlea@1abmedia.com
